TickerFacts.

BridgeBio Pharma, Inc. (BBIO): Cost of Revenue

Annual figures by period end, from SEC filings.

$20.96M
Year ended 2025-12-31
$39.66M
Trailing 12 months to 2026-06-30
+82.8%
3-year compound annual growth
2021-12-31: $3.11M2022-12-31: $3.43M2023-12-31: $2.45M2024-12-31: $3.88M2025-12-31: $20.96M$20.96M
2021-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$20.96M+440.5%2026-02-24, From 2025-01-01
2024-12-31$3.88M+58.5%2026-02-24, From 2024-01-01
2023-12-31$2.45M-28.8%2026-02-24, From 2023-01-01
2022-12-31$3.43M+10.3%2025-02-20, From 2022-01-01
2021-12-31$3.11Mn/a2024-02-22, From 2021-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
BridgeBio Pharma, Inc. (BBIO)2025-12-31$20.96M+440.5%
Travere Therapeutics, Inc. (TVTX)2025-12-31$10.34M+33.5%
Nature's Sunshine Products Inc (NATR)2025-12-31$132.42M+2.1%
HUTCHMED (China) Ltd (HCM)2025-12-31$336.35M-3.6%
Zai Lab Ltd (ZLAB)2025-12-31$190.52M+29.5%
Organogenesis Holdings Inc. (ORGO)2024-12-31$115.74M+8.7%
Insmed Inc (INSM)2025-12-31$122.94M+43.4%
Opko Health, Inc. (OPK)2025-12-31$400.94M-18.9%
TG Therapeutics, Inc. (TGTX)2025-12-31$100.71M+161.7%

Compare BBIO, TVTX, NATR, HCM side by side · Screen every company in Pharmaceutical Preparations ↗